Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.

Inoue M, Shiramoto M, Oura T, Nasu R, Nakano M, Takeuchi M

Diabetes therapy : research, treatment and education of diabetes and related disorders4 Apr 2019Cited by 10 (Europe PMC)

PMID30949907PMCIDPMC6531535DOI10.1007/s13300-019-0605-7PepBankPUB-30949907

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, dulaglutide reduced postprandial glucose AUC versus placebo at weeks 1, 2, and 4.
In plain wordsIn Japanese patients with T2D, dulaglutide reduced post-meal glucose more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial glucose AUC
Study
n = 12
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
The decrease in AUC (0-4 h) from baseline to week 4 following dulaglutide administration was statistically significant compared with placebo at weeks 1, 2, and 4 (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990701
02HumanRandomized controlled trialMechanism
In Japanese patients with T2D, dulaglutide increased insulin versus placebo at weeks 2 and 4.
In plain wordsIn Japanese patients with T2D, dulaglutide increased insulin more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseInsulin levels
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Insulin and C-peptide levels were also significantly increased (P < 0.05) with dulaglutide versus placebo at weeks 2 and 4.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990702
03HumanRandomized controlled trialMechanism
In Japanese patients with T2D, dulaglutide increased C-peptide versus placebo at weeks 2 and 4.
In plain wordsIn Japanese patients with T2D, dulaglutide increased C-peptide more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseC-peptide levels
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Insulin and C-peptide levels were also significantly increased (P < 0.05) with dulaglutide versus placebo at weeks 2 and 4.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990703
04HumanRandomized controlled trialMechanism
In Japanese patients with T2D, glucagon levels did not differ significantly between dulaglutide and placebo.
In plain wordsIn Japanese patients with T2D, glucagon levels did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeGlucagon levels
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences between groups in glucagon and triglyceride levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990704
05HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, triglyceride levels did not differ significantly between dulaglutide and placebo.
In plain wordsIn Japanese patients with T2D, blood triglycerides did not differ significantly between dulaglutide and placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeTriglyceride levels
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences between groups in glucagon and triglyceride levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990705
06HumanRandomized controlled trialSafety outcome
In Japanese patients with T2D, treatment-emergent adverse events were slightly more frequent with dulaglutide than placebo.
In plain wordsIn Japanese patients with T2D, adverse events were slightly more frequent with dulaglutide than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment-emergent adverse events
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
The incidence of treatment-emergent adverse events was slightly higher with dulaglutide versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990707
07HumanRandomized controlled trialEfficacy outcome
In Japanese patients with T2D, average glucose decreased the day after dulaglutide administration and remained similar for 4 days.
In plain wordsIn Japanese patients with T2D, average glucose fell after dulaglutide and remained similar for 4 days.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDaily average glucose
Study
n = 12
Analysis
Exploratory
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 4 weeksAs given in this study (human).
Source sentences
Summary
Daily average glucose concentrations were decreased on the day after the first administration of dulaglutide and remained at similar levels for 4 days.
1 context sentence(design, population, supporting numbers)
Summary · context
The pharmacodynamic (PD) effects of once-weekly dulaglutide (0.75 mg) in Japanese patients with T2D on diet and exercise therapy (N = 12) were evaluated by assessing postprandial data up to week 4 in a phase 4, single-center, randomized, cross-over, single-blind, placebo-controlled study.
Report a problemFND-3094990706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03315780

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Eli Lilly and Companyn = 1228 Oct 2017 to 28 Feb 2018

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 16 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.